TGF-β1: Mediator of a feedback loop in eosinophilic esophagitis—or should we really say mastocytic esophagitis? - 07/08/11
Key words : Mast cells, eosinophilic esophagitis, human
Le texte complet de cet article est disponible en PDF.
Supported in part by National Institutes of Health grants U19 AI070235, AI045898, and DK076893; the Campaign Urging Research for Eosinophilic Disease (CURED) (M.E.R.); the Buckeye Foundation (M.E.R.); and the Food Allergy Project/Food Allergy Initiative (M.E.R.). |
|
Disclosure of potential conflict of interest: J. P. Abonia has received research support from the National Institutes of Health (NIH), Ception Therapeutics, and the Children’s Digestive Health and Nutrition Foundation. M. E. Rothenberg is a speaker and consultant for Merck; is a consultant for Centocor, Ception Therapeutics, Nycomed, Array Biopharma, Biocrystal Pharmaceuticals, Endo Pharmaceuticals, and Pieres AG; has received research support from the NIH, the Food Allergy & Anaphylaxis Network, and the Dana Foundation; and is on the medical advisory board of the American Partnership for Eosinophilic Disorders and on the executive council of the International Eosinophil Society. J. P. Franciosi has declared that he has no conflict of interest. |
Vol 126 - N° 6
P. 1205-1207 - décembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?